Life Sciences

Sidley Austin is considered a regulatory powerhouse across Asia, particularly in Hong Kong and Mainland China, and maintaining valuable links to the USA. Advises global medical device and pharmaceutical companies on high-stakes investigations, and handles an impressive array of advisory work, with a focus on pan-Asian antitrust issues. Also adept in transactional life sciences issues, including strategic partnerships and market entry. Expertise in cybersecurity and data privacy augments the team's capabilities in the sector.

One client says: "They have extremely rich experience in advising the life science industry and also the most cutting-edge knowledge on the development of China's life science industry."

"They understand very well the historical evolution of various critical regulatory topics and their complex context, which means their legal advice goes beyond the interpretation of laws and is rather a comprehensive guidance to our business," highlights another client.

Sidley Austin LLP assisted Beijing Advaccine Biotechnology with its licensing deal with Inovio Pharmaceuticals, an American biotechnology company, regarding a COVID-19 vaccine.

Yang Chen leads the firm's China life sciences practice and is a main contact for clients.